Optimizing patient-reported outcomes for sarcoidosis
Abstract
Patients with sarcoidosis can present with a wide range of symptoms that impact their quality of life (QoL). QoL represents one of the most important treatment priorities for patients. Therefore, measuring what matters to patients is of great importance, though it can be challenging due to the diverse presentation of the disease. Patient-reported outcome measures (PROMs) are designed to assess patients' subjective symptoms and their impact on their lives. Over the past decade, PROMS have been increasingly used in clinical trials and daily practice. In this review, we will provide an overview of frequently used generic- and disease-specific PROMS in the field op sarcoidosis. We summarize their psychometric properties and discuss limitations and future opportunities.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.